Opposing roles for mammary epithelial-specific PPARγ signaling and activation during breast tumour progression

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Apostoli, Anthony J ^a   Roche, Jennifer M ^a   Schneider, Mark M ^a   SenGupta, Sandip K ^a   Di Lena, Michael A ^a   Rubino, Rachel E ^b   Peterson, Nichole T ^b   Nicol, Christopher J B ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Breast cancer; Chemotherapy; Knockout mouse model; Mammary epithelial cells; PPAR

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; BRCA1 PROTEIN; CYCLOOXYGENASE 2; EOTAXIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; VASCULOTROPIN; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST EPITHELIUM CELL; BREAST TUMOR; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; BLOOD; DISEASE COURSE; EPITHELIUM CELL; EXPERIMENTAL MAMMARY NEOPLASM; GENE DELETION; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR VOLUME; UDDER;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BRCA1 PROTEIN; CYTOKINES; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; GENE DELETION; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; ORGAN SPECIFICITY; PPAR GAMMA; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 84928819817     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-015-0347-8     Document Type: Article

References (51)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon, France. 2013. http://globocan.iarc.fr. Accessed 16/04/2015.
2. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137(1):354-66. doi:10.1210/endo.137.1.8536636.
3. Jain S, Pulikuri S, Zhu Y, Qi C, Kanwar YS, Yeldandi AV, et al. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol. 1998;153(2):349-54.
4. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1998;1(3):465-70.
5. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A. 1998;95(15):8806-11.
6. Kotta-Loizou I, Giaginis C, Theocharis S. The role of peroxisome proliferator-activated receptor-gamma in breast cancer. Anticancer Agents Med Chem. 2012;12(9):1025-44.
7. Campbell MJ, Carlberg C, Koeffler HP. A role for the PPARgamma in cancer therapy. PPAR Res. 2008;2008:314974. doi:10.1155/2008/314974.
8. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007;28(12):551-8. doi:10.1016/j.it.2007.09.003.
9. Bortolini M, Wright MB, Bopst M, Balas B. Examining the safety of PPAR agonists - current trends and future prospects. Expert Opin Drug Saf. 2013;12(1):65-79. doi:10.1517/14740338.2013.741585.
10. Kim JH, Hubbard NE, Ziboh V, Erickson KL. Conjugated linoleic acid reduction of murine mammary tumor cell growth through 5-hydroxyeicosatetraenoic acid. Biochim Biophys Acta. 2005;1687(1-3):103-9. doi:10.1016/j.bbalip.2004.11.007.
11. Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR, et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun. 2001;286(5):916-22. doi:10.1006/bbrc.2001.5491.
12. Nicol CJ, Yoon M, Ward JM, Yamashita M, Fukamachi K, Peters JM, et al. PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis. 2004;25(9):1747-55. doi:10.1093/carcin/bgh160.
13. Skelhorne-Gross G, Reid AL, Apostoli AJ, Di Lena MA, Rubino RE, Peterson NT, et al. Stromal adipocyte PPARgamma protects against breast tumorigenesis. Carcinogenesis. 2012;33(7):1412-20. doi:10.1093/carcin/bgs173.
14. Apostoli AJ, Skelhorne-Gross GE, Rubino RE, Peterson NT, Di Lena MA, Schneider MM, et al. Loss of PPARgamma expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment. Int J Cancer. 2014;134(5):1055-66. doi:10.1002/ijc.28432.
15. Cui Y, Miyoshi K, Claudio E, Siebenlist UK, Gonzalez FJ, Flaws J, et al. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem. 2002;277(20):17830-5. doi:10.1074/jbc.M200186200.
16. Fiennes AG. Growth rate of human tumour xenografts measured in nude mice by in vivo cast modelling. Br J Surg. 1988;75(1):23-4.
17. Pignatelli M, Cocca C, Santos A, Perez-Castillo A. Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line. Oncogene. 2003;22(35):5446-50. doi:10.1038/sj.onc.1206824.
18. Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, et al. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev. 2004;18(5):528-40. doi:10.1101/gad.1167804.
19. Yin Y, Yuan H, Zeng X, Kopelovich L, Glazer RI. Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification. Cancer Res. 2009;69(2):687-94. doi:10.1158/0008-5472.CAN-08-2446.
20. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol. 2002;22(8):2607-19.
21. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem. 2003;278(36):34268-76. doi:10.1074/jbc.M300043200.
22. Nicol CJ, Adachi M, Akiyama TE, Gonzalez FJ. PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens. 2005;18(4 Pt 1):549-56. doi:10.1016/j.amjhyper.2004.10.032.
23. Rosak C, Standl E, Reblin T, Stammer H, Seidel DK. Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes. Int J Clin Pract. 2006;60(9):1040-7. doi:10.1111/j.1742-1241.2006.01092.x.
24. Dream_Trial_Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096-105. doi:10.1016/S0140-6736(06)69420-8.
25. Welters HJ, El Ouaamari A, Kawamori D, Meyer J, Hu J, Smith DM, et al. Rosiglitazone promotes PPARgamma-dependent and -independent alterations in gene expression in mouse islets. Endocrinology. 2012;153(10):4593-9. doi:10.1210/en.2012-1243.
26. Takata Y, Liu J, Yin F, Collins AR, Lyon CJ, Lee CH, et al. PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci U S A. 2008;105(11):4277-82. doi:10.1073/pnas.0708647105.
27. Ghosh S, Lu Y, Katz A, Hu Y, Li R. Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells. Am J Physiol Endocrinol Metab. 2007;292(1):E246-52. doi:10.1152/ajpendo.00242.2006.
28. Hoellen F, Kelling K, Dittmer C, Diedrich K, Friedrich M, Thill M. Impact of cyclooxygenase-2 in breast cancer. Anticancer Res. 2011;31(12):4359-67.
29. Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003;97(12):2978-87. doi:10.1002/cncr.11437.
30. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002;62(6):1676-81.
31. Thill M, Fischer D, Becker S, Cordes T, Dittmer C, Diedrich K, et al. Prostaglandin metabolizing enzymes in correlation with vitamin D receptor in benign and malignant breast cell lines. Anticancer Res. 2009;29(9):3619-25.
32. Diaz-Cruz ES, Shapiro CL, Brueggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab. 2005;90(5):2563-70. doi:10.1210/jc.2004-2029.
33. Hazra S, Dubinett SM. Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells. Prostaglandins Leukot Essent Fatty Acids. 2007;77(1):51-8. doi:10.1016/j.plefa.2007.05.006.
34. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol. 2001;11(10):764-8.
35. Meade EA, McIntyre TM, Zimmerman GA, Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem. 1999;274(12):8328-34.
36. Patel KM, Wright KL, Whittaker P, Chakravarty P, Watson ML, Ward SG. Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPAR(gamma) agonists: evidence for disparate functional effects which are independent of NF-(kappa)B and PPAR(gamma). Cell Signal. 2005;17(9):1098-110. doi:10.1016/j.cellsig.2004.12.002.
37. Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, Stearman R, et al. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol. 2008;73(3):709-17. doi:10.1124/mol.107.042002.
38. Ackerman WE, Zhang XL, Rovin BH, Kniss DA. Modulation of cytokine-induced cyclooxygenase 2 expression by PPARG ligands through NFkappaB signal disruption in human WISH and amnion cells. Biol Reprod. 2005;73(3):527-35. doi:10.1095/biolreprod.104.039032.
39. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, et al. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A. 2000;97(9):4844-9.
40. Pujols L, Benitez P, Alobid I, Martinez-Anton A, Roca-Ferrer J, Mullol J, et al. Glucocorticoid therapy increases COX-2 gene expression in nasal polyps in vivo. Eur Respir J. 2009;33(3):502-8. doi:10.1183/09031936.00017408.
41. Matthews L, Berry A, Tersigni M, D'Acquisto F, Ianaro A, Ray D. Thiazolidinediones are partial agonists for the glucocorticoid receptor. Endocrinology. 2009;150(1):75-86. doi:10.1210/en.2008-0196.
42. Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol. 2003;23(17):6159-73.
43. Ahmed F, Wyckoff J, Lin EY, Wang W, Wang Y, Hennighausen L, et al. GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice. Cancer Res. 2002;62(24):7166-9.
44. Nolen BM, Lokshin AE. Targeting CCL11 in the treatment of ovarian cancer. Expert Opin Ther Targets. 2010;14(2):157-67. doi:10.1517/14728220903512983.
45. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res. 2008;79(3):360-76. doi:10.1093/cvr/cvn120.
46. Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol. 2004;36(10):1882-6. doi:10.1016/j.biocel.2003.10.019.
47. Peeters LL, Vigne JL, Tee MK, Zhao D, Waite LL, Taylor RN. PPAR gamma represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis. 2005;8(4):373-9. doi:10.1007/s10456-005-9027-4.
48. Kawai H, Li H, Chun P, Avraham S, Avraham HK. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene. 2002;21(50):7730-9. doi:10.1038/sj.onc.1205971.
49. Singh-Ranger G, Salhab M, Mokbel K. The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat. 2008;109(2):189-98. doi:10.1007/s10549-007-9641-5.
50. Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers. 2011;3(4):3856-93. doi:10.3390/cancers3043856.
51. McKenzie AN, Culpepper JA, De Waal MR, Briere F, Punnonen J, Aversa G, et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci U S A. 1993;90(8):3735-9.